Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-105-3-462_3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare malignant ovarian tumors: a review.
Jpn J Clin Oncol
January 2025
Department of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior.
View Article and Find Full Text PDFCXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Breast Cancer Res
January 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Background: CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome resistance, necessitating a deeper understanding of its mechanisms.
View Article and Find Full Text PDFMind relaxation effect of Jatamansi Taila Shirodhara on psychological distress in Triple Negative Breast Cancer (TNBC) patients - results of an open-labelled, randomised controlled clinical trial.
J Ayurveda Integr Med
January 2025
Bharatiya Sanskriti Darshan Trust's Integrated Cancer Treatment and Research Centre, Wagholi, Pune, Maharashtra, India.
Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer clinically defined as lacking expression of Estrogen receptor (ER), Progesterone receptor (PR), and Human Epidermal growth factor Receptor (HER2). Psychological distress is a major risk factor of TNBC, patients diagnosed with TNBC are under tremendous stress due to the aggressive nature of the disease. Stress hormones decrease the efficacy of therapeutics.
View Article and Find Full Text PDFAn Optimized Protocol for Simultaneous Propagation of Patient-derived Organoids and Matching CAFs.
Bio Protoc
January 2025
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Recurrent hormone receptor-positive (HR+) breast cancer is a leading cause of cancer mortality in women. Recurrence and resistance to targeted therapies have been difficult to study due to the long clinical course of the disease, the complex nature of resistance, and the lack of clinically relevant model systems. Existing models are limited to a few HR+ cell lines, organoid models, and patient-derived xenograft models, all lacking components of the human tumor microenvironment.
View Article and Find Full Text PDF'Bone Health-Across a Woman's Lifespan'.
Clin Endocrinol (Oxf)
January 2025
Centre for Endocrinology & Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Despite a high burden of osteoporosis and minimal trauma fractures worldwide, there is still a treatment gap in timely diagnosis and optimal treatment. There is also a lack of international consensus and guidelines on the management of bone fragility in premenopausal women. This review article provides an overview of the current understanding of factors impacting women's bone health across the adult lifespan, as well as dilemmas in the diagnosis, assessment and management of osteoporosis in premenopausal and postmenopausal women, premature ovarian insufficiency and bone health following breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!